Back to Results
First PageMeta Content
Exemestane / Pfizer / Selective estrogen receptor modulators / Phenols / Tamoxifen / Hormonal therapy / Mastectomy / Estrogen / Androstenedione / Medicine / Pharmacology / Aromatase inhibitors


AROMASIN® (exemestane tablets) NDA[removed]S-006 October 4, 2005 S-006 Approved Labeling EBC Indication
Add to Reading List

Document Date: 2009-03-31 15:16:10

Open Document

File Size: 196,03 KB

Share Result on Facebook

Company

Early Breast Cancer The Intergroup / /

Country

Denmark / /

Event

FDA Phase / /

IndustryTerm

active site / plasma accounting / breast cancer therapy / Treatment of Advanced Breast Cancer / /

MedicalCondition

tumor / Disease / Early Breast Cancer / severe renal insufficiency / metastatic disease / Neoadjuvant Advanced Disease / Renal Insufficiency / severe hepatic insufficiency / positive disease / hormone-dependent breast cancer / Action Breast cancer / PgR positive Disease / advanced breast cancer / breast cancer / Early Breast Cancer ITT Population Disease / Hepatic Insufficiency / Prior Chemotherapy For advanced disease / /

MedicalTreatment

hormonal therapy / breast cancer therapy / Chemotherapy / Radiotherapy / surgery / Hormone replacement therapy / Mastectomy / adjuvant therapy / /

Organization

World Health Organization / /

Person

Breast Cancer / /

Position

Major / /

Product

megestrol acetate / estradiol / testosterone / polyethylene glycol / exemestane / ACTH / ketoconazole / mannitol / estrone / AROMASIN / S-006 / AROMASIN® (exemestane tablets) / /

ProvinceOrState

Nebraska / /

Technology

Pharmacokinetics / Chemotherapy / treating cancer / Pharmacodynamics / /

SocialTag